



Advancing Biopharma  
Oncology Pipelines



# Where trust meets results

10+ years of proven expertise with 300+ biopharma partners, including 85% of the top 20

- End-to-end multi-modal testing services through CAP-accredited and CLIA-certified laboratories in the United States and the United Kingdom
- Comprehensive, validated off-the-shelf assays and integrated data analysis
- Advanced customization for your program's needs
- Experience across 25+ oncology indications, including solid, hematologic, and rare cancers
- Beyond lab data — de-risk your biomarker strategy with multi-modal real-world data and accelerate your timeline with qualified, timely patient insights and alerts

*“Partnering with NeoGenomics has been a positive experience for my studies in terms of ease of contracting, robust data generation, flexible data transfer options, close collaboration on troubleshooting, excellent communication for company- and study-level changes, and support. My projects with NeoGenomics are top of list across the board.”*

— **Top-20 pharmaceutical organization**

## Accelerating therapeutic development at every stage, regardless of complexity



# Flexible, technology-agnostic approach

Leveraging our broad platform portfolio, we deliver the optimal solution for your programs with unbiased, data-driven results that fast-track development.



## Histopathology

- State-of-the-art **integrated workflow** from tissue processing through microtomy to a wide range of downstream modalities
- **400+ validated biomarkers**
- **In-house sub-specialized pathology expertise** for precise evaluation and reporting
- **Advanced image analysis** for quantitative scoring



## Genomics

- Comprehensive testing services across **NGS, dPCR, qPCR, Sanger sequencing, microarray, NanoString nCounter<sup>®</sup>, and GeoMx<sup>®</sup> DSP**
- **Tumor-informed MRD detection** (RaDaR<sup>®</sup> ST) and **CGP** including **Neo Comprehensive<sup>®</sup> - Heme Cancers** (Lymphoid and Myeloid) and **TSO 500 (tissue and liquid biopsy)**
- **Bioinformatics expertise** for advanced data analysis and strategic consulting
- **Timely access to real-world data**, enabling responsive decision-making
- **Longitudinal patient insights** to inform study design and strategy



## Flow cytometry

- High-quality **conventional** and **spectral** flow cytometry
- **LDT-validated** targeted **clinical assays** including **MRD**; data reviewed by **board-certified hematopathologists**
- **Comprehensive RUO/exploratory services** across immunophenotyping, **receptor occupancy**, cell therapy, cell signaling, and biomarker evaluation
- **PBMC** and **BMMC** processing



## Spatial analysis

- **Multiplexed and hyperplexed IF** enabling detection of 60+ protein biomarkers
- Integrated **whole-tissue workflow, AI-driven image analysis**, and **advanced spatial analytics** exclusively available by Palettra™
- Highly multiplexed, spatially resolved **RNA and protein tissue profiling**



## FISH & cytogenetics

- FISH **coverage of over 90 different loci** and **over 60 tests**, including LDT and IVD testing options
- **Disease-focused panels**
- **Cytogenetics services** for **myeloid, lymphoid, and plasma cell** indications



## Multi-modal real-world evidence

- Where **lab data meet clinical insights**
- A repository of **3.2 million whole slide images**
- **Accelerate trial enrollment** through histology or biomarker-driven alerts

*“The NeoGenomics team is easy to work with, the lab is consistent on providing timely and correct results, and the project management team provides prompt communication.”*

— **Small biotechnology organization**

BMMC = bone marrow mononuclear cell; CGP = comprehensive genomic profiling; dPCR = digital polymerase chain reaction; FISH = fluorescence in situ hybridization; IF = immunofluorescence; IVD = in vitro diagnostic; LDT = laboratory developed test; MRD = molecular residual disease; NGS = next-generation sequencing; PBMC = peripheral blood mononuclear cell; qPCR = quantitative polymerase chain reaction; RUO = research use only.

To learn more about NeoGenomics Pharma Services, visit us online at [NeoGenomics.com/Partners](https://www.neogenomics.com/Partners), call us at 866.776.5907, option 3, or email us at [contactpharma@neogenomics.com](mailto:contactpharma@neogenomics.com).

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and oncology data solutions. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service, sample-processing laboratory in Cambridge, England, United Kingdom. ©2026 NeoGenomics Laboratories, Inc. All rights reserved.



9490 NeoGenomics Way  
Fort Myers, FL 33912

Phn: 866.776.5907  
Fax: 239.690.4237

[NeoGenomics.com](https://www.neogenomics.com)

All trademarks are the property of their respective owners.

CORP-MRKT-0380 01.26